NCT06523517View on ClinicalTrials.gov

Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Gaucher Disease
Interventions
DRUG

Eliglustat Tartrate Capsules

The initial dose is 42 mg taken orally twice a day. After 2 weeks of treatment, if the blood trough concentration is less than 5 ng/mL, the dose will be increased to 84 mg taken orally twice daily.

Trial Locations (1)

Unknown

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06523517 - Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3 | Biotech Hunter | Biotech Hunter